Introduction
============

Eosinophilic cystitis (EC) is a type of cystitis with unknown etiology, which was first reported by Brown *et al* ([@b1-etm-0-0-6578]) in 1960 ([@b2-etm-0-0-6578]). The disease rarely occurs in children and, to the best of our knowledge, only 59 cases have been previously reported. As for children, adults are rarely affected by EC. Incidence in males is larger compared with females and onset develops at a mean age of 6.0±0.5 years ([@b3-etm-0-0-6578],[@b4-etm-0-0-6578]). EC has been reported to be local manifestations of systemic 'hypereosinophilic' syndromes and allergic diseases, and is associated with bladder trauma, infections and certain medications, including iodine or anesthetic ointments ([@b5-etm-0-0-6578],[@b6-etm-0-0-6578]). The clinical manifestations of EC include hematuria, irritative voiding symptoms and bladder wall thickening, which is often misdiagnosed as tumors ([@b7-etm-0-0-6578]). The pathological manifestation of EC includes eosinophilic infiltration into layers of the bladder wall ([@b4-etm-0-0-6578]). EC may be caused by immune system regulation disorders, which induce antigen stimulation and lead to immunoglobulin E (IgE)-mediated eosinophil activation and degranulation of mast cells, triggering the release of inflammatory mediators and injuring the bladder wall ([@b8-etm-0-0-6578]). Adult patients with EC may present with a variety of urinary symptoms, including frequent urination, urgent urination, odynuria, hematuria, dysuria and suprapubic pain; children with EC often have similar symptoms ([@b9-etm-0-0-6578],[@b10-etm-0-0-6578]). Pathologic biopsy findings are therefore paramount for differential diagnosis ([@b11-etm-0-0-6578]). Treatments for EC include observation, identification of allergens, antibiotics, antihistamines and steroids ([@b12-etm-0-0-6578]). For intractable hematuria, transurethral resection of bladder lesions and partial cystectomy may also be used ([@b8-etm-0-0-6578]). The current study presents two cases of EC, which were diagnosed and treated at the Children\'s Hospital of Hunan (Changsha, China) between January 2016 and March 2017. Clinical manifestations, pathological features, corresponding treatments and follow-ups are reported.

Case report
===========

### Case 1

Patient 1 was a 6-year-old male who first presented with intermittent gross hematuria, frequent urination, urgent urination, odynuria and abdominal pain in January 2016 at the Children\'s Hospital of Hunan (Changsha, China). The frequency of urination reached 30 times a day, however the increased rate of urination was primarily at night. Urination was difficult, although the patient was able to form a stream. The patient had no history of hemorrhage or allergy and no lumbago or fever on admission ([Table I](#tI-etm-0-0-6578){ref-type="table"}). The patient was diagnosed as having a urinary infection and given one week of anti-inflammatory treatment (Cefmetazole, 100 mg/kg/d) two days prior to the aggravation of dysuresia symptoms. Ultrasonography revealed a thickened bladder wall. Following anti-inflammatory treatment (Cefmetazole, 100 mg/kg/d) for further 3 days, the symptoms disappeared. The patient had normal blood pressure on admission and routine blood tests revealed eosinophil ratios of 24.6, 33.0 and 29.4% (normal range, 0.5--5%) ([@b13-etm-0-0-6578]) on day 1, at the end of week 1 and at the end of week 2, respectively. In addition, the red blood cell count and hemoglobin were observed using peripheral blood smears (data not shown); all results were normal. During hospitalization, urine samples were collected by urinary bladder catheterization and sent to the hospital laboratory. Urine cultures were prepared on blood agar medium and MacConkey agar (PlastLabor Microbiologica, Rio de Janeiro, Brazil). A Vitek (bioMérieux, Marcy-l\'Étoile, France) was used to identify and test the susceptibility of strains. A urinary tract infection was established at ≥50,000 colony forming units/ml of a single microbial growth. These urine culture tests yielded negative results and a routine urine test and microscopy revealed 20--25 red blood cells in each high-power field of view (data not shown). The specific gravity of urine was 1.025 and a urine nitrite test was negative (data not shown). Renal functions were normal and the concentration of complement C3 was 122 mg/dl. A tuberculin test had negative results and urine polymerase chain reaction (PCR) revealed no adenovirus or *Mycobacterium tuberculosis* (data not shown). Levels of *Dermatophagoides pteronyssinus* (D1) and *Dermatophagoides culinae* (D2) allergens were grade 2 ([@b14-etm-0-0-6578]). Ultrasonography indicated obvious thickening and abundant blood flow in the bladder wall ([Fig. 1A and B](#f1-etm-0-0-6578){ref-type="fig"}). Computed tomography revealed local mucosal lesions with thickening of the right and posterior wall of the bladder ([Fig. 2A-D](#f2-etm-0-0-6578){ref-type="fig"}). Retrograde angiography of the bladder determined that the bladder volume decreased and the bladder wall was irregular ([Fig. 3A and B](#f3-etm-0-0-6578){ref-type="fig"}). Cystoscopy also revealed that the bladder volume became smaller and the mucosa at the bladder floor and neck became red (data not shown). Based on the above examinations, rhabdomyosarcoma of the bladder was initially considered as a diagnosis. Biopsy of the lesions through the urethra was performed and specimen were fixed at room temperature in 10% formalin for 12--24 h, embedded in paraffin at 62°C for 3 h, cut into 4-µm-thick sections and stained with a hematoxylin (Shanghai Regal Biology Technology Co., Ltd., Shanghai, China) and eosin (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) according to the manufacturer\'s protocol. Specimens were examined histopathologically using a light microscope (magnification, ×400; DM 2000 LED; Leica Microsystems, Inc., Buffalo Grove, IL, USA) to assess the types of lesions ([@b15-etm-0-0-6578]). Lesions revealed congestion and edema of the bladder mucosa ([Fig. 4](#f4-etm-0-0-6578){ref-type="fig"}) and infiltration of the blood vessels and eosinophils into the muscular layer ([Fig. 5](#f5-etm-0-0-6578){ref-type="fig"}) accompanied by focal muscle necrosis ([Fig. 6](#f6-etm-0-0-6578){ref-type="fig"}). A bone marrow biopsy demonstrated eosinophilia ([Fig. 7](#f7-etm-0-0-6578){ref-type="fig"}; [Table II](#tII-etm-0-0-6578){ref-type="table"}). Following diagnosis, the patient was given anti-inflammatory (Cefmetazole, 100 mg/kg/d) and cetirizine hydrochloride (1 ml/day) treatments for a week, followed by 6 weeks of prednisone dose-reduction therapy ([@b16-etm-0-0-6578]). One month later, re-examination revealed that the symptoms had disappeared and imaging results were normal ([Fig. 8A and B](#f8-etm-0-0-6578){ref-type="fig"}). The blood eosinophil content was 1.19%. Following continued intake of low-dose prednisone (5 mg/day) for 2 months, the level of blood eosinophils was normal. Imaging examination also revealed completely normal results ([Fig. 9A and B](#f9-etm-0-0-6578){ref-type="fig"}; [Table III](#tIII-etm-0-0-6578){ref-type="table"}).

### Case 2

Patient 2 was a 7-year-old male who presented with acute dysuria, suprapubic pain, frequent urination, urgent urination, urgent incontinence and odynuria. The patient had no history of allergies and had normal body development ([Table I](#tI-etm-0-0-6578){ref-type="table"}). On admission in March 2017, the patient had a normal blood pressure and the eosinophil ratios were 7.9, 5.6 and 0.09% on day 1, at the end of week 1 and at the end of week 2, respectively. Normal red blood cells and normal hemoglobin were observed in the peripheral blood smears (data not shown). A urine culture test yielded negative results, while a routine urine test and microscopy revealed no abnormalities (data not shown). The specific gravity of the urine was 1.030 and a nitrite test in the urine yielded negative results (data not shown). The patient\'s renal functions were normal and the concentration of complement C3 was 109 mg/dl. PPD experiments yielded negative results and urine PCR revealed no adenovirus or *Mycobacterium tuberculosis* (data not shown). No clear allergens were observed in the allergen screening (data not shown). Computed tomography and retrograde angiography of the bladder revealed local mucosal lesions with thickening of each side and the posterior wall of the bladder (data not shown). Cystoscopy revealed that the bladder volume was reduced and the mucosa at the bladder floor and neck was red (data not shown). The symptoms of EC included acute dysuria, suprapubic pain, frequent urination, urgent urination, urge incontinence and odynuria. Biopsy of the lesions through the urethra revealed infiltration of blood vessels and eosinophils into the muscular layer, accompanied by focal muscle necrosis (data not shown). EC was diagnosed, however there was no eosinophilic proliferation in the bone marrow biopsy ([Table II](#tII-etm-0-0-6578){ref-type="table"}). Anti-inflammatory (Cefmetazole, 100 mg/kg/day) and cetirizine hydrochloride (1 ml/day) treatments were administered for a week. Two months later, the symptoms had disappeared (data not shown). Imaging examinations revealed normal results and the blood eosinophils were normal ([Table III](#tIII-etm-0-0-6578){ref-type="table"}). The data which are not presented for case 2 were comparable to the images presented for case 1.

Discussion
==========

EC is an uncommon primary inflammatory disorder of the bladder with uncertain etiology. The incidence of EC in male adults is increased compared with female adults. Similarly, the incidence of EC in male children is increased compared with females; the average age of onset in children is 6 years old ([@b17-etm-0-0-6578],[@b18-etm-0-0-6578]). The exact cause of EC remains unclear, however certain studies have suggested that anaphylaxis may be a trigger ([@b5-etm-0-0-6578]--[@b7-etm-0-0-6578]). Allergens may include food, dust mites, pollen, condom antigens, iodine and anesthetic creams. Asthma and celiac disease are also associated with EC ([@b8-etm-0-0-6578]). In the present study, the patient in case 1 was sensitive to *Dermatophagoides pteronyssinus* and *Dermatophagoides culinae*, while the patient in case 2 had no specific allergies. The pathogenesis of EC involves IgE-mediated eosinophil activation, with subsequent mast cell degranulation and muscle damage ([@b8-etm-0-0-6578]). Patients with EC often exhibit a series of urinary symptoms, including frequent urination, hematuria, suprapubic pain, dysuria and daytime and nocturnal enuresis; children with EC may have a clear suprapubic mass ([@b19-etm-0-0-6578]). The clinical manifestations in the cases presented in the present study were consistent with EC; however, the clinical manifestations of EC are often varied and may be easily confused with nonspecific cystitis ([@b2-etm-0-0-6578]). Children with suprapubic masses should also be differentiated from those with malignant bladder tumors. EC is a rare condition that can mimic invasive bladder cancer symptoms. EC diagnosis may be considered if a bladder tumor is associated with eosinophilia ([@b20-etm-0-0-6578]). The eosinophil count in the blood was significantly increased in each of the 2 cases and a bone marrow biopsy revealed increased eosinophils. In a number of patients with EC, peripheral blood eosinophilia occurs without reaching the level of eosinophilia syndrome. Patient 2 only received treatment by anti-inflammatory and cetirizine hydrochloride without steroid therapy. During hospitalization, the eosinophils were found to be decreased in a routine blood test and the patient\'s symptoms gradually improved. It has previously been suggested that EC may also present a self-healing trend ([@b3-etm-0-0-6578]). In the present study, patient 1 presented with similar symptoms 3 years earlier; an ultrasonography revealed thickening of the bladder wall and following 3 days of anti-inflammatory treatment, the symptoms disappeared. In addition, patient 1 was allergen-positive. The authors hypothesize that the onset of the disease in case 1 was associated with allergens and that, with the elimination of inflammatory mediators, symptoms may disappear ([@b3-etm-0-0-6578]). It has previously been reported that urine cultures are positive in EC patients ([@b4-etm-0-0-6578]). However, the urine cultures in each of the cases presented herein were negative. Eosinophils are rarely observed in urine sediments and are rapidly degraded or rarely detached from the mucosa ([@b21-etm-0-0-6578]). Certain EC patients have hematuria symptoms ([@b22-etm-0-0-6578],[@b23-etm-0-0-6578]). If an imaging examination reveals bladder wall thickening, which is similar to mass infiltration, a tumor is suggested. Cystoscopy results usually suggest bladder rhabdomyosarcoma ([@b6-etm-0-0-6578]). Intense inflammatory changes, including congestion and edema of the bladder wall, may result in intense inflammatory changes in the bladder wall and associated with this, lesion may produce excrescences, which resemble vesical rhabdomyosarcoma ([@b24-etm-0-0-6578]). As EC is very rare in children there are no ideal guidelines for its treatment and follow-up and treatment is typically based on experience ([@b25-etm-0-0-6578]). First-line treatments typically involve the removal of any suspected allergens, followed by the use of antihistamines and corticosteroids. It has been reported that corticosteroids may accelerate the remission of symptoms and stabilize lysosomal membranes due to their anti-inflammatory effects ([@b16-etm-0-0-6578]). For refractory cases, cyclosporine A is administered orally for 8 months ([@b26-etm-0-0-6578]). For children with peripheral blood eosinophilia, montelukast sodium is used ([@b27-etm-0-0-6578]). Researchers have also tried intravesical instillation of dimethyl sulfoxide twice a week ([@b27-etm-0-0-6578]). EC in children is normally benign and self-limiting, however it may still develop into bladder fibrosis and secondary urinary tract obstruction. The diagnosis and treatment of EC depends on clinical suspicions and histopathological examination.

In conclusion, EC in children is similar to a tumor, however it has its own characteristics. Although it is a rare disease it should be considered when urinary tract symptoms and bladder wall thickening are observed in children. Bladder biopsy and histopathological evaluation are important for the diagnosis of EC and allow for the selection of an appropriate treatment.
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![Ultrasonography of the bladder wall of patient 1. (A) Ultrasound revealed irregular thickening of the bladder wall. (B) Color Doppler ultrasound revealed abundant blood flow in the bladder wall. Red indicates flow towards the probe; blue indicates flow away from the probe.](etm-16-04-2978-g00){#f1-etm-0-0-6578}

![Computed tomography recorded for patient 1. (A) Diffuse thickening and a rough edge were observed in the bladder wall. (B) The volume of the bladder cavity was small and the density of the thickened bladder wall was uneven. (C) Contrast enhanced computed tomography revealed abundant blood flow in the bladder wall and uneven enhancement. (D) The bladder wall was smooth and no obvious filling or defect was observed.](etm-16-04-2978-g01){#f2-etm-0-0-6578}

![Retrograde angiography of the bladder of patient 1. (A) Front view. (B) Left view. Bladder volume was decreased. The bladder wall was irregular and thickened, with diffusive mucosal lesions.](etm-16-04-2978-g02){#f3-etm-0-0-6578}

![Hematoxylin and eosin staining of the bladder wall tissues obtained from patient 1 (magnification, ×100). A small amount of transitional epithelium was observed on the mucosa. Sub-epithelial fibrous hyperplasia was also observed, which was accompanied by inflammatory cell infiltration. The cells were primarily eosinophil granulocytes, however scattered lymphocytes and plasma cells were also observed.](etm-16-04-2978-g03){#f4-etm-0-0-6578}

![Hematoxylin and eosin staining of the bladder wall tissues obtained from patient 1 (magnification, ×400). Eosinophils infiltrated into the right posterior muscular bundle.](etm-16-04-2978-g04){#f5-etm-0-0-6578}

![Infiltration of eosinophils into the subepithelial fibrous stroma as observed in patient 1. Magnification, ×400.](etm-16-04-2978-g05){#f6-etm-0-0-6578}

![Bone marrow biopsy of patient 1. Myeloid granulocytic hyperplasia was active, the eosinophil ratio was increased and there was no clear abnormality at each stage. Magnification, ×400.](etm-16-04-2978-g06){#f7-etm-0-0-6578}

![Follow-up with patient 1 at one month post treatment. (A) Ultrasonography. (B) Computed tomography. The bladder was well filled. The bladder wall was smooth, even and only slightly thickened. No clear filling or defects were found.](etm-16-04-2978-g07){#f8-etm-0-0-6578}

![Follow-up with patient 1 at three months post treatment. (A) Ultrasonography. (B) Computed tomography. The bladder wall was smooth, even and not thickened. No filling or defects were observed.](etm-16-04-2978-g08){#f9-etm-0-0-6578}

###### 

Clinical features and manifestations of the disease following admission to hospital.

               Symptoms                                     
  ---- --- --- ---------- ---- ---- ---- ---- ------- ----- -----
  I    M   6   \+         --   \+   --   \+   Acute   Yes   Yes
  II   M   7   --         \+   \+   \+   \+   Acute   No    Yes

M, male; 1, hematuria; 2, abdominal pain; 3, irritative symptoms of the bladder; 4, urinary incontinence; 5, dysuria and urinary retention. +, positive result; -, negative result.

###### 

Imaging examination, laboratory examination, cystoscopy and pathological examination.

       Eosinophilic granulocytes in blood (%)           Ultrasonography   Computed tomography                                                                
  ---- ---------------------------------------- ------- ----------------- --------------------- ------ ---- ------ ------ ---- ------ ------ ---- ------ --- ------
  I    24.60                                    33.00   29.40             1.19                  2.34   --   a, b   a, b   --   a, b   a, b   --   a, b   c   d, e
  II   7.90                                     5.60    0.09              1.87                  2.65   --   a, b   a, b   --   a, b   a, b   --   a, b   c   d, e

1, admission examination; 2, one week after treatment; 3, four weeks after treatment; 4, eight weeks after treatment; 5, twelve weeks after treatment. a, decreased bladder volume; b, irregular bladder wall; c, hyperemia and edema of mucosa under endoscope; d, infiltration of blood vessels and eosinophils into the muscular layer; e, focal muscle necrosis.

###### 

Treatment, follow-up and prognosis of patients.

  Case   Treatments                                                   Duration of treatment (weeks)   Follow-up   Prognosis
  ------ ------------------------------------------------------------ ------------------------------- ----------- -----------
  I      Anti-inflammation, cetirizine hydrochloride and prednisone   12                              Monthly     Recovered
  II     Anti-inflammation and cetirizine hydrochloride               12                              Monthly     Recovered
